Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors

Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands

(2015) Sara Sattin et al.   CHEMISTRY-A EUROPEAN JOURNAL

Targeting FGFR Signaling in Cancer

(2015) M. Touat et al.   CLINICAL CANCER RESEARCH

Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance

(2015) Marco Rusnati et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis

(2015) Roberto Ronca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors

(2015) F. Li et al.   Cancer Discovery

Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors

(2015)   Oncotarget

Investigating the Dynamic Aspects of Drug-Protein Recognition through a Combination of MD and NMR Analyses: Implications for the Development of Protein-Protein Interaction Inhibitors

(2014) Massimiliano Meli et al.   PLoS One

Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations

(2013) Han Kiat Ho et al.   DRUG DISCOVERY TODAY

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

(2013) Maria Vittoria Dieci et al.   Cancer Discovery

Ligand Clouds around Protein Clouds: A Scenario of Ligand Binding with Intrinsically Disordered Proteins

(2013) Fan Jin et al.   PLoS Computational Biology

Diversification of the Structural Determinants of Fibroblast Growth Factor-Heparin Interactions

(2012) Ruoyan Xu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule

(2012) Katiuscia Pagano et al.   PLoS One

Fibroblast growth factors and their receptors in cancer

(2011) Jørgen Wesche et al.   BIOCHEMICAL JOURNAL

Targeting angiogenesis with compounds from the extracellular matrix

(2011) Dorina Belotti et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors

(2010) Giorgio Colombo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships

(2010) Timothy R. Rudd et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity

(2009) Marco Rusnati et al.   SENSORS

Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain

(2007) Barbara Margosio et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY